White Billy, Hsia Yingfen, Kinra Sanjay, Saxena Sonia, Christie Deborah, Viner Russell M, Wong Ian C K
Department of Population Health Sciences, UCL Institute of Child Health, London, UK.
Department of Adolescent Medicine, University College London Hospital, London, UK.
BMJ Paediatr Open. 2017 Oct 25;1(1):e000104. doi: 10.1136/bmjpo-2017-000104. eCollection 2017.
Antiobesity drug (AOD) prescribing in children and young people (CYP) in primary care is rising with high rates of discontinuation. Little is known about prescribing in this group in terms of patient demographics and comorbidities, reasons for initiation and discontinuation, or adherence to national guidelines.
Questionnaire survey to general practitioners (GPs) identified using a nationally representative primary care database covering 6% of UK population.
UK-wide primary care.
Patients were eligible if prescribed an AOD aged ≤18 years between 2010 and 2012. A total of 151 patients from 108 unique practices were identified via national prescribing database, with responses for 119 patients (79%) from 84 practices; 94 of 119 (79%) were eligible for inclusion.
Survey of GP prescribing habits of AODs to CYP. We audited orlistat usage against the National Institute for Health and Care Excellence (NICE) guidance.
47% were prescribed metformin, 59% orlistat and 5% both drugs. Orlistat was largely prescribed by GPs independently (49/55 prescriptions, 89%) and metformin by GPs on specialist recommendation (12/44, 27%). Orlistat was largely prescribed in those over 16 years of age without physical comorbidities. Metformin was initiated for treatment of polycystic ovarian syndrome (70%), insulin resistance (25%) and impaired glucose control (9%). Median supply of metformin was 10.5 months (IQR 4-18.5 months) and 2.0 months (1.0-4.0) for orlistat (p≤0.001). Drug terminations were largely due to families not requesting repeat prescriptions. NICE guidance adherence was low; 17% of orlistat prescriptions were initiated by specialists, and 56% had evidence of obesity-related comorbidity. GPs reported lower confidence in prescribing AOD to CYP compared with adults (10-point Likert score median 3 vs 8, p<0.001).
Prescribing of AOD in primary care is challenging with low adherence to NICE guidance. Further work is needed to better support GPs in the use of AOD in CYP.
基层医疗中针对儿童和青少年(CYP)开具抗肥胖药物(AOD)的情况日益增多,但停药率很高。对于该群体在患者人口统计学特征和合并症、开始用药和停药原因或遵循国家指南方面的用药情况知之甚少。
对使用覆盖英国6%人口的具有全国代表性的基层医疗数据库确定的全科医生(GP)进行问卷调查。
全英国基层医疗。
2010年至2012年间年龄≤18岁且开具了AOD的患者符合条件。通过国家处方数据库确定了来自108家不同诊所的151名患者,来自84家诊所的119名患者(79%)进行了回复;119名患者中的94名(79%)符合纳入条件。
对全科医生针对儿童和青少年开具AOD的用药习惯进行调查。我们对照英国国家卫生与临床优化研究所(NICE)指南审核了奥利司他的使用情况。
47%的患者开具了二甲双胍,59%开具了奥利司他,5%同时开具了这两种药物。奥利司他大多由全科医生独立开具(49/55张处方,89%),二甲双胍则是在专科医生建议下由全科医生开具(12/44,27%)。奥利司他大多开给16岁以上无身体合并症的患者。二甲双胍用于治疗多囊卵巢综合征(70%)、胰岛素抵抗(25%)和血糖控制受损(9%)。二甲双胍的中位供应时长为10.5个月(四分位间距4 - 18.5个月),奥利司他为2.0个月(1.0 - 4.0个月)(p≤0.001)。停药主要是因为家属未要求重复开处方。对NICE指南的遵循度较低;17%的奥利司他处方由专科医生开具,56%有肥胖相关合并症的证据。与成人相比,全科医生报告在给儿童和青少年开具AOD时信心较低(10分制李克特量表中位数为3分对8分,p<0.001)。
基层医疗中开具AOD具有挑战性,对NICE指南的遵循度较低。需要进一步开展工作,以更好地支持全科医生在儿童和青少年中使用AOD。